RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy

J Control Release. 2022 Feb:342:228-240. doi: 10.1016/j.jconrel.2022.01.012. Epub 2022 Jan 10.

Abstract

RNA interference (RNAi) is being extensively investigated as a potential therapeutic strategy for cancer treatment. However, RNAi-based therapeutics have not yet been used to treat cancer because of their instability and the difficulty of microRNA (miRNA) delivery. Plasmonic nanoparticle-based RNAi nanotherapeutics have been developed for accurate and sensitive diagnosis and a strong therapeutic effect on cancers by leveraging their ease-of-use and specific properties such as photothermal conversion. In this review, recent strategies and advances in plasmonic nanoparticle-based miRNA delivery are briefly presented to facilitate the detection and treatment of several cancers. The challenges and potential opportunities afforded by the RNAi-based theragnosis field are discussed. We expect that the RNAi-integrated plasmonic nanotherapeutics discussed in this review can provide insights for the early diagnosis and effective treatment of cancer.

Keywords: Nanobiosensor; Photothermal therapy; Plasmonic nanoparticle; RNA interference (RNAi); Small interference RNA (siRNA); Theragnosis; microRNA (miRNA).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug Delivery Systems
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / therapeutic use
  • Nanoparticles*
  • Neoplasms* / diagnosis
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • RNA Interference
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / therapeutic use

Substances

  • MicroRNAs
  • RNA, Small Interfering